Rotigotine transdermal patch: A review of its use in the management of Parkinson's disease

CNS Drugs

Volumn 21, Issue 12, 2007, Pages 1039-1066

  Baldwin, Claudine M ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Dopamine receptor agonists, general; Parkinson's disease; Rotigotine, general; Transdermal

Indexed keywords

ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; SIGMA OPIATE RECEPTOR; TOLCAPONE;

ADD ON THERAPY; BINDING AFFINITY; CAUDATE NUCLEUS; CLINICAL GLOBAL IMPRESSION SCALE; DAILY LIFE ACTIVITY; DIZZINESS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHAGIA; FATIGUE; GASTROINTESTINAL MOTILITY DISORDER; HALLUCINATION; HUMAN; IN VITRO STUDY; MONOTHERAPY; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PHARMACODYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL; PUTAMEN; RECEPTOR AFFINITY; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STEADY STATE; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING;

EID: 36248987178     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721120-00007     Document Type: Review

References (48)

1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003 Apr; 348 (14): 1356-64
2. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996; 14 (2): 317-35
3. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66 (7): 983-95
4. Silver D. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist 2006; 12 (4): 214-23
5. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5 (8): 677-87
6. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23 (5): 357-75
7. Schwarz Pharma. US prescribing information [online]. Available from URL: http://www.neupro.com [Accessed 2007 Aug 2]
8. Schwarz Pharma. EU prescribing information [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Aug 2]
9. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. Epub 2007 Jun 4
10. Scheller DKA. Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist for the treatment of Parkinson's disease [abstract no. P94]. Mov Disord 2006; 21 Suppl. 13: S80
11. European Medicines Agency. European public assessment report (EPAR): Neupro [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Aug 2]
12. Naidu Y, Chaudhuri KR. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Expert Opin Drug Deliv 2007; 4 (2): 111-8
13. Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994 Mar; 9 (2): 147-54
14. Rose S, Scheller DK, Breidenbach A, et al. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol 2007 Mar; 18 (2): 155-60
15. Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation [abstract no. 250]. Ann Neurol 2004; 56 Suppl. 8: S54
16. Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol 2007 Feb; 203 (2): 415-22
17. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine [abstract no. 101]. J Clin Pharmacol 2005; 45 (9): 1091
18. Cawello W, Braun M, Horstmann R, et al. Pharmacokinetics, safety and tolerability of rotigotine after transdermal patch administration in Japanese and Caucasian healthy subjects. Mov Disord 2006 Jan 1; 21 Suppl. 15: 547-8
19. Cawello W, Elshoff JP, Boekens H, et al. Characteristics of rotigotine elimination after patch removal [abstract no. P1164]. 10th Congress of the European Federation of Neurological Societies; 2006 Sep 2-5; Glasgow
20. Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease [abstract no. P1245]. Poster presented at the 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
21. Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function [abstract no. 102]. J Clin Pharmacol 2005; 45 (9): 1091
22. Braun M, Cawello W, Horstmann R. Lack of pharmacokinetic interaction between the dopamine agonist rotigotine and levodopa/carbidopa [abstract no. 4775]. Presented at the 16th International Congress on Parkinson's Disease and Related Disorders; 2005 Jun 5-9; Berlin
23. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003 Dec; 60 (12): 1721-8
24. Babic T, Boothmann B, Polivka J, et al. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol 2006 Jul-Aug; 29 (4): 238-42
25. Calabrese VP, Lloyd KA, Brancazio P, et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of Parkinsonism. Mov Disord 1998 Sep; 13 (5): 768-74
26. Guldenpfennig WM, Poole KH, Sommerville KW, et al. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005 May 30; 28 (3): 106-10
27. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001; 24 (3): 163-9
28. Bianchine J, Poole K. Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson's disease. Neurology 2002; 58 Suppl. 3: A162-3
29. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. Epub 2007 Oct 12
30. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 Jan 23; 68 (4): 272-6
31. Watts RL, Pahwa R, Lyons KE, et al. Long-term safety and efficacy of the rotigotine transdermal patch in early-stage Parkinson's disease. Poster presented at the 58th Annual Meeting of the American Academy of Neurology; 2006 Apr 1-8; San Diego (CA)
32. Watts RL, LeWitt PA, Giladi N, et al. Treatment with rotigotine transdermal system may attenuate progression of disability in patients with early-stage Parkinson's disease [abstract no. P02.103]. Neurology 2005 Mar 22; 64 (6 Suppl. 1): 107
33. Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007 May; 64 (5): 676-82
34. Quinn N, for the SP 511 Investigators. Rotigotine transdermal delivery system (TDS) (SPM 962): a multicenter, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson's disease [abstract no. P-TU-223]. Parkinsonism Relat Disord 2001; 7 Suppl. 1: S66. Plus poster presented at the 14th International Congress on Parkinson's Disease; 2001 Jul 27-Aug 1; Helsinki
35. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007 Apr 17; 68 (16): 1262-7
36. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 Jun; 6 (6): 513-20
37. Pahwa R. Transdermal continuous dopamine stimulation for the management of Parkinson disease [online]. Available from URL: http://www.cmellc.com [Accessed 2007 Aug 2]
38. Obeso JA, Grandas F, Herrero MT, et al. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6: 889-97
39. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007; 22 (1): 1-9
40. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35) [online]. Available from URL: http://guidance.nice.org/uk [Accessed 2007 Sep 18]
41. American Academy of Neurology. Practice parameters: Parkinson's disease [online]. Available from URL: http://www.neurology.org [Accessed 2007 Sep 18]
42. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005; 22 (9): 731-40
43. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17 Suppl. 4: S1-166
44. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006; 45 (2): 109-36
45. Waters C. Patch delivery: rotigotine-patch delivery of a dopamine agonist [online]. Available from URL: http://www.movementdisorders.org [Accessed 2007 Aug 2]
46. Winkler JD, Weiss B. Reversal of supersensitive apomorphine-induced rotational behavior in mice by continuous exposure to apomorphine. J Pharmacol Exp Ther 1986; 238: 242-7
47. Sethi KD. Patch delivery: novel methods for drug delivery in Parkinson's disease [online]. Available from URL: http://www.movementdisorders.org [Accessed 2007 Aug 2]
48. Sylvester B. Internal medicine world report: investigational patch for Parkinson's eliminates morning "down time" [online]. Available from URL: http://www.imwr.com [Accessed 2007 Aug 2]